Estimates Revisions Lineage Cell Therapeutics, Inc.
Stocks
LCTX
US53566P1093
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.200 USD | -2.44% |
|
-1.64% | -28.14% |
| 05-12 | Lineage Cell Therapeutics, Inc., Q1 2026 Earnings Call, May 12, 2026 | |
| 05-12 | Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- LCTX Stock
- Consensus Lineage Cell Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
